News
06-02-2008, 03:21 PM
Peregrine Pharmaceuticals, Inc. has announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
More... (http://www.news-medical.net/?id=38822)
More... (http://www.news-medical.net/?id=38822)